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Summary
The human APOBEC3G protein restricts the replication of
Vif-deficient HIV-1 by deaminating nascent viral cDNA cyto-
sines to uracils, leading to viral genomic strand G-to-A
hypermutations [1–4]. However, the HIV-1 Vif protein triggers
APOBEC3G degradation, which helps to explain why this in-
nate defense does not protect patients [5]. The APOBEC3G-
Vif interaction is a promising therapeutic target, but the ben-
efit of the enabling of HIV-1 restriction in patients is unlikely
to be known until Vif antagonists are developed. As a neces-
sary prelude to such studies, cell-based HIV-1 evolution
experiments were done to find out whether APOBEC3G
can provide a long-term block to Vif-deficient virus replica-
tion and, if so, whether HIV-1 variants that resist restriction
would emerge. APOBEC3G-expressing T cells were infected
with Vif-deficient HIV-1. Virus infectivity was suppressed in
45/48 cultures for more than five weeks, but replication
was eventually detected in three cultures. Virus-growth
characteristics and sequencing demonstrated that these
isolates were still Vif-deficient and that in fact, these viruses
had acquired a promoter mutation and a Vpr null mutation.
Resistance occurred by a novel tolerance mechanism in
which the resistant viruses packaged less APOBEC3G and
accumulated fewer hypermutations. These data support the
development of antiretrovirals that antagonize Vif and
thereby enable endogenous APOBEC3G to suppress HIV-1
replication.
Results
APOBEC3G has been shown to decrease the infectivity of Vif-
deficient HIV-1 by 10- to several-100-fold (e.g., [2–4, 6–9]).
However, in almost all reported experiments there was clearly
a population of viruses that appeared unrestricted. These
apparent escapees could be attributable to low levels of virus
replication in the presence of APOBEC3G, to a failure of
APOBEC3G to express in some cells, and/or to assays operat-
ing near resolution limits. Regardless of the explanations, the
overall and long-term potency of this important antiviral pro-
tein is unknown.
To address these questions and gain further insights into the
mechanism of HIV-1 restriction, we used a long-term continu-
ous cell-culture system to ask whether Vif-deficient viruses
could evolve resistance to APOBEC3G. The human T cell line
*Correspondence: rsh@umn.eduCEM-SS was transfected stably with an APOBEC3G-expres-
sion construct or a vector control. APOBEC3G-expressing
clones restricted the short-term spreading infection of Vif-de-
ficient HIV-1IIIB but not that of the Vif-proficient virus (Figure 1A
and Table S1 available online; originally shown in [3]). In con-
trast, vector-control clones supported the replication of both
viruses. It is noteworthy that the CEM-SS clones selected for
these experiments expressed near-physiologic APOBEC3G
levels, similar to those in the parental line CEM (nonpermissive
for Vif-deficient virus replication), the unrelated T cell line H9,
or activated CD4-positive primary T lymphocytes (Figure 1B
and Figure S1).
Two independent APOBEC3G-expressing CEM-SS clones
were each split into 24 wells, infected with Vif-deficient HIV-
1IIIB, and maintained continuously for six weeks. Cell-free
supernatants were used in the periodic assaying for the pres-
ence of viable virus with the use of reporter cells, in which
a Tat-activated HIV-1 LTR promoter drives GFP expression
and therefore provides a quantitative measure of virus infectiv-
ity (see Supplemental Experimental Procedures). Although
most cultures showed no signs of virus replication, one culture
from experiment 1 and two cultures from experiment 2 began
to produce virus around the five-week time point (Figure 1C).
These virus isolates were called A3G-R1, A3G-R2, and A3G-
R3.
To eliminate cell-based explanations for the apparent resis-
tance phenotypes (such as a loss of APOBEC3G expression),
supernatants containing A3G-R1, -R2, and -R3 were purified
and used to infect fresh APOBEC3G-expressing cells. All three
of the virus isolates were now clearly capable of growth on
APOBEC3G-expressing cells, indicating that they had evolved
a strong, heritable resistance to APOBEC3G (Figure 1D). These
virus-replication kinetics were similar to those of the Vif-profi-
cient virus on APOBEC3G-expressing cells, and they were
stable over a minimum of five passages, each using fresh
APOBEC3G-expressing cells (Table S1). These data demon-
strated that APOBEC3G is capable of providing a long-term
block to Vif-deficient HIV-1 replication, which is only rarely
alleviated by resistance mutation(s).
To find out whether the APOBEC3G-resistant viral isolates
had restored Vif function, we assessed whether the resistant
isolates could replicate in two human T cell lines, CEM and
H9, in which Vif is required to overcome APOBEC3G, the
related restriction factor APOBEC3F, and potentially other
cellular proteins (e.g., Figure 1, Figure 2, Figure S1, and refs.
[3, 9]). Curiously, none of the APOBEC3G-resistant isolates
replicated in CEM or H9 cells, indicating that Vif was still non-
functional and that something other than APOBEC3G was still
inhibiting virus replication (Figure 2A and Figure S1). Proviral
DNA sequencing confirmed that the resistant isolates retained
the original vif nonsense mutations.
APOBEC3F and APOBEC3G are thought to function simi-
larly, by gaining access to assembling HIV-1 particles and
deaminating nascent cDNA (e.g., [6, 9–11]). APOBEC3B and
APOBEC3DE have also been implicated in HIV-1 restriction
(e.g., [10, 12, 13]). To test whether any of these APOBEC3
proteins could mediate restriction of the APOBEC3G-resistant
isolates, viral spreading-infection experiments were done with
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and analogous experiments were independently done with
clones that expressed HA-tagged APOBEC3G, APOBEC3F,
APOBEC3B, or APOBEC3DE (Figure 2 and Figure S2).
APOBEC3B or APOBEC3DE did not inhibit the replication of
the Vif-deficient parental virus, let alone the APOBEC3G-resis-
tant derivatives (Figure S2). These data suggested that neither
of these is relevant to HIV-1 restriction in the CEM-SS system,
but additional experiments will be necessary for determining
whether these proteins influence HIV-1 in other cell types.
In contrast, APOBEC3F inhibited the replication of both the
Vif-deficient virus and the APOBEC3G-resistant isolates but
not the Vif-proficient parent (Figure 2 and Figure S2). Inhibition
was not attributable to differences in protein levels (Figure S2).
Figure 1. Vif-Deficient HIV-1 Isolates that Resist APOBEC3G
(A) Short-term spreading-infection data for Vif-deficient (circles) or
Vif-proficient (inverted triangles) viruses. Throughout the manuscript,
a unique symbol represents each virus, open symbols and dashed lines
represent virus growth on vector-control cells (e.g., V2), and filled sym-
bols and solid lines represent virus growth on APOBEC3-expressing
cells (e.g., G1, G2).
(B) An immunoblot showing APOBEC3G levels in CEM, vector-control
CEM-SS clones (V1 and V2), CEM-SS (–), and three independently
derived APOBE3G-expressing CEM-SS clones (G1, G2, and G3). The
same membrane was stripped and probed for Tubulin (TUB). Comple-
mentary immunoblot data comparing model cell lines to primary cells
are shown in Figure S1.
(C) Highlights of the long-term spreading-infection experiments for
Vif-deficient viruses on vector-control- or APOBEC3G-expressing
CEM-SS cell lines. Of the cultures, 45/48 showed no virus replication
on APOBEC3G-expressing cells (flat lines not graphed). The three
APOBEC3G-resistant isolates that eventually emerged were A3G-R1
(squares), A3G-R2 (triangles), and A3G-R3 (diamonds).
(D) Spreading infections of A3G-R1, -R2, or -R3 on CEM-SS clones
expressing APOBEC3G (G1, G2) or a vector control (V2). Parental vi-
ruses were also analyzed in parallel, and these data resembled those
in Figure 1A (not shown). See the APOBEC3G panels in Figure S2 for
complementary data and Table S1 for additional information.
Figure 2. APOBEC3G-Resistant Isolates Are Still Susceptible to APOBEC3F
(A and B) Replication kinetics of the parental viruses and A3G-R1, -R2, and -R3 on CEM cells or APOBEC3F-expressing CEM-SS cells (F1 or F2). These
experiments were done in parallel, so the vector-control data (V2) shown in the CEM panels are also applicable to the APOBEC3F panels. The A3G-R2
and -R3 data on APOBEC3F lines are presented in one panel to make space for Figure 2C. A3G-R1, -R2, and -R3 also spread with rapid kinetics on
APOBEC3G-expressing cells (G2; not shown). The higher overall titers of the APOBEC3G-resistant viruses warranted expanded y axes. Symbol and line
designations are identical to those in Figure 1. See Figure S1 and Figure S2 for complementary data.
(C) An immunoblot of APOBEC3F levels in two APOBEC3F-expressing CEM-SS clones (F1 and F2), parental CEM-SS cells (–), and two nonpermissive cell
lines (H9 and CEM). The same membrane was stripped and probed for Tubulin (TUB).
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pendent Resistance to APOBEC3G
(A) A schematic of HIV-1IIIB indicating the coding
regions and relevant restriction sites (GenBank
Accession EU541617). Asterisks denote the tan-
dem stop mutations in vif.
(B) Summaries of the types of base substitutions
found in A3G-R1, -R2, and -R3 proviral DNA.
Each horizontal line is a composite of four inde-
pendent proviral DNA sequences from large or
small PCR amplicons (solid and dashed lines,
respectively). G-to-A substitutions are depicted
by vertical bars, and other substitutions are de-
picted by closed circles. Vertical arrows highlight
the common A-to-T/C and vpr-inactivating muta-
tions. See Figure S4 for an overview of 800 kb of
sequencing data.
(C) Replication kinetics of molecular clone-de-
rived viruses with the indicated genotypes. Sym-
bol and line designations are nearly identical to
those in Figure 1, the exception being that the
double mutants share the same symbols as the
APOBEC3G-resistant triple mutant (diamonds
for A3G-R3M). See Figure S3 for supporting
data, including experiments with A3G-R1M,
A3G-R2M, and their double-mutant derivatives.These data therefore (1) indicated that resistance is specific to
APOBEC3G and that the mechanisms of restriction by APO-
BEC3F and APOBEC3G differ at some fundamental level, (2)
supported the hypothesis that APOBEC3F is at least partly
responsible for the inability of Vif-deficient viruses to replicate
on CEM cells, and (3) discouraged most trivial explanations for
APOBEC3G resistance, such as improved fitness or growth
rate (given that crossresistance to APOBEC3F would probably
have been observed in such scenarios).
The APOBEC3G-resistance mutations were identified by
sequencing of proviral DNA. Remarkably, the APOBEC3G-
resistant isolates only had two types of mutations in common:
an A200T or A200C (A200T[C]) noncoding transversion and
a Vpr truncation mutation (Figure 3 and Table S2). It is likely
that these two mutations arose independently, because the
nature of these and several associated mutations suggested
that both APOBEC3G-dependent and -independent mecha-
nisms contributed to the genesis of the resistance-conferring
mutations (Table S2). For inquiring whether a Vpr-truncation
and an A200 transversion combined to confer resistance,
these mutations were incorporated into Vif-deficient molecular
clones and used for spreading-infection experiments (Fig-
ure 3C and Figure S3; an ‘‘M’’ suffix label distinguishes molec-
ular-clone-derived viruses from original isolates). All of the
molecular clones with both mutations, A3G-R1M, A3G-R2M,
and A3G-R3M, spread efficiently on APOBEC3G-expressing
cells, whereas viruses with either mutation alone were unable
to replicate. Thus, both mutations were required for Vif-defi-
cient viruses to overcome APOBEC3G-dependent restriction.
Mammalian retroviruses use multiple strategies to escape
the APOBEC3 proteins of their hosts. HIV-1 and SIV use Vif
to degrade APOBEC3s, foamy viruses use Bet to inhibit
APOBEC3s, and others such as HTLV, MuLV, and MPMV sim-
ply appear to exclude APOBEC3s from encapsidation (e.g., [5,
14–19]). However, the frequent G-to-A hypermutations
observed during identification of the APOBEC3G-resistancemutations strongly suggested that the resistance mechanism
described here would be unique. Indeed, extensive proviral
DNA-sequence analyses showed that the resistant viruses
were being hypermutated at a significant frequency, 2-fold
lower than that of the Vif-deficient parental virus (1.5 G-to-A
versus 3.3 G-to-A per kb, respectively) but still much higher
than the Vif-proficient virus (0.03 G-to-A per kb) (Figure S4).
These hypermutation data implied that significant but per-
haps lower levels of APOBEC3G were being encapsidated.
For addressing this directly, APOBEC3G encapsidation was
quantified in spreading-infection experiments with CEM-SS
cells expressing a catalytically defective but otherwise fully
intact APOBEC3G protein that does not inhibit Vif-deficient
HIV-1 (A3G-E259Q; e.g., [2, 8, 20]). Immunoblots of virion-
associated proteins from the spreading-infection peaks dem-
onstrated that the resistant molecular clones packaged 2- to
3-fold less APOBEC3G than did the Vif-deficient parent
(Figure 4A and Figure S5). Moreover, the APOBEC3G-resis-
tance phenotype and the partial-encapsidation defect were
apparent in a single round of virus replication in APOBEC3G-
expressing CEM-SS cells (Figure S6 and Supplemental Dis-
cussion). Taken together, the hypermutation and packaging
data demonstrated that the resistant viruses had evolved
a novel tolerance mechanism for escaping APOBEC3G-
dependent restriction. This mechanism may be particularly
applicable to a population of viruses, given that the population
clearly expands while many individual viruses are undoubtedly
being restricted.
Interestingly, the APOBEC3G packaging defect was also ap-
parent in Vif-deficient A200T(C) viruses (Figure 4A). This corre-
lated inversely with data showing that the resistant isolates
and A200T(C) mutants yielded higher virus titers (Figure 4B).
One way that these two results may be linked is for the
A200T(C) mutation to upregulate HIV-1 transcription, which
would produce more substrate for particle production and in
turn cause less APOBEC3G to be packaged (i.e., more particle
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The A200T(C) mutation is located on the promoter proximal
end of a demonstrated transcriptional-activator-binding site
(DBF [21]), which supports such a mechanism. Therefore,
to test whether the A200T(C) mutation triggers higher levels
of transcription, we made a series of LTR-promoter-driven
GFP-expression constructs containing A200, T200, or C200,
transfected HEK293 cells, and monitored GFP expression
with flow cytometry. The T200 and C200 constructs each
caused an 8- to 10-fold increase in GFP expression
(Figure 4C). It is notable that most HIV-1 isolates already
have a pyrimidine at position 200 (http://www.hiv.lanl.gov/
content/hiv-db). We therefore tested whether the reciprocal
mutation would diminish promoter activity and found that
Figure 4. A200T(C) Contributes to APOBEC3G Resistance by Enhancing
HIV-1 Transcription, Increasing Virus Titers, and Diminishing APOBEC3G
Encapsidation
(A) Immunoblots showing the level of virus-particle-associated APOBEC3G-
E259Q or p24Gag from a spreading-infection experiment with the indicated
viruses. Relative to the Vif(-) virus with an APOBEC3G/p24Gag ratio normal-
ized to 1 (n = 3), the Vif(-)/Vpr(-), A200T(C)/Vif(2) and A200T(C)/Vif(2)/Vpr(2)
viruses had mean ratios of 1.1 6 0.36 (n = 9), 0.25 6 0.10 (n = 9), and
0.32 6 0.17 (n = 8), respectively. See Figure S5 for additional quantification
and Figure S6 for complementary single-cycle data.
(B) Relative titers of the indicated viruses produced after a single round of re-
plication on CEM-SS cells expressing APOBEC3G-E259Q. Each histogram
bar shows the mean and SD of three independently derived supernatants
(some error bars were too small to graph). The titer for the Vif-proficient virus
was normalized to 1 to facilitate comparisons.
(C) Expression levels of the indicated LTR-GFP reporter constructs in
HEK293 cells. Each histogram bar shows the mean and SD of three indepen-
dent replicas. The GFP-expression level of the A200 HIV-1IIIB construct was
normalized to 1 to facilitate comparisons. The inset depicts the LTR-GFP-
expression construct, with position of nucleotide 200 marked by an asterisk.a T200A compromised the activity of the HIV-1LAI promoter
(Figure 4C). Taken together, these data indicated that tran-
scriptional upregulation underlies both the observed titer
increases and the APOBEC3G encapsidation defect, thereby
constituting an integral part of the APOBEC3G-resistance
mechanism.
Discussion
Our studies demonstrate that APOBEC3G is capable of block-
ing the replication of Vif-deficient HIV-1 over an extended dura-
tion. Virus replication was only detectable after two mutations
appeared: a noncoding A200T(C) transversion and a Vpr null
mutation. The fact that significant virus evolution was required
for Vif-deficient viruses to bypass restriction by APOBEC3G
demonstrates that this arm of the innate immune response is
capable of imposing a lethal block to virus replication. Our
studies therefore provide an important proof of principle that
can be appreciated with analogies drawn to HIV-1 drug resis-
tance. The potency of APOBEC3G can now be compared to
that of bona fide antiretroviral drugs such as reverse transcrip-
tase inhibitors, given that both impose blocks to virus replica-
tion such that resistance mutations provide the only means of
escape. The combination of APOBEC3G and APOBEC3F may
be further likened to two antiretroviral drugs that block replica-
tion through distinct paths (e.g., nucleoside and nonnucleod-
side reverse transcriptase inhibitors), because resistance to
APOBEC3G did not confer crossresistance to APOBEC3F.
Our studies therefore provide strong additional justifications
for efforts to develop Vif-neutralizing therapeutics.
The novel combination of resistance mutations reported
here also provides a unique opportunity to better understand
the mechanism of APOBEC3G-dependent HIV-1 restriction.
It is remarkable that APOBEC3G did not select for a restoration
of Vif function. This strongly indicates that Vif has other, poten-
tially more important, roles in the biology of HIV-1 and related
lentiviruses. Together with prior work [6, 9–11], our studies
suggest that at least one of those roles will be APOBEC3F
neutralization.
Our data indicate that the A200T(C) mutation contributes
to APOBEC3G resistance by elevating LTR transcription, in-
creasing virus production, and ultimately causing less APO-
BEC3G encapsidation (Figure S7). Diminished APOBEC3G
levels thereby contribute to an overall shift from lethal to sub-
lethal levels of restriction (i.e., a shift to tolerable APOBEC3G
levels). This suggests that anything the virus does to minimize
APOBEC3G packaging is likely to prove beneficial. Some vi-
ruses, like HTLV, MuLV, and MTMV appear to have taken this
to the extreme by simply excluding APOBEC3G from particles
[14–17].
A Vpr-inactivating mutation was also required for Vif-defi-
cient HIV-1 to evolve resistance to APOBEC3G. Vpr-inactiva-
tion was not observed in Vif-deficient viruses that replicated
on non-APOBEC3G-expressing CEM-SS cells (not shown).
These unexpected results suggested that Vpr might actually
facilitate APOBEC3G-dependent restriction by, for instance,
packaging a cellular factor (Figure S7). Such a model is appeal-
ing because Vpr is abundant in virions and it has been shown
to interact with many proteins (e.g., uracil DNA glycosylase
UNG2, Vpr-binding protein 1, and others; reviewed in [22]).
However, the most obvious Vpr-binding candidate, UNG2, is
not involved in APOBEC3G-dependent restriction [7, 8, 23,
24]. Much additional work will therefore be necessary for the
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testing of other tenable models.
In addition to its clear relevance to HIV-1, the novel tolerance
mechanism described here has several broad implications. It
highlights the distinct possibility that some retroviruses might
have evolved to coexist with and possibly even benefit from
the mutagenic activity of the APOBEC3 proteins. For example,
the majority of reverse-transcribing viruses and transposons
lack obvious APOBEC3-neutralizing factors such as Vif or
Bet (e.g., [5, 18, 19]). Moreover, it is unlikely that all remaining
retroelements escape restriction by HTLV-, MuLV-, or MPMV-
like avoidance mechanisms (e.g., [14–17]). Thus, on the basis
of current data, the APOBEC3G ‘‘resistance by tolerance’’
mechanism described here might well apply to many viruses.
Indeed, G-to-A hypermutations are evident in multiple viruses,
such as other lentiviruses, the hepadnavirus HBV, the gam-
maretrovirus SNV, the endogenous murine retrovirus Pmv, and
the DNA tumor virus HPV (e.g., [25–29]). Therefore, the ability
to tolerate and perhaps even regulate APOBEC3-dependent
restriction has clear implications for virus evolution, immune
escape, and drug resistance.
Supplemental Data
Experimental procedures, a supplemental discussion, two tables, and seven
figures are included with this article online at http://www.current-biology.
com/cgi/content/full/18/11/819/DC1/.
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